Weil Advises DRI Healthcare on Royalty Financing Agreement with Viridian Therapeutics for Thyroid Eye Disease Treatments

"Weil advised DRI Healthcare Acquisitions LP on a royalty financing agreement with Viridian Therapeutics, aimed at funding the commercial launches of its thyroid eye disease treatments, veligrotug and VRDN-003. The Weil team was led by David J. Cohen and included several other partners and associates."

Weil, a prominent law firm, advised DRI Healthcare Acquisitions LP in its royalty financing agreement with Viridian Therapeutics, Inc., a biotechnology company dedicated to developing innovative treatments for serious and rare diseases. The transaction involves a financing agreement that is expected to provide the necessary funds for the upcoming commercial launches of Viridian’s treatments for thyroid eye disease, specifically veligrotug and VRDN-003. The Weil team was led by David J. Cohen, Co-Managing Partner of Weil’s Miami office. The team also included associate Justin Kanoff, Banking & Finance partner Meredith Mackey, and Life Science Transactions & IP partner Kane Wishart.

Weil Advises DRI Healthcare on Royalty Financing Agreement with Viridian Therapeutics for Thyroid Eye Disease Treatments

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads